Diosgenin alleviates hypercholesterolemia via SRB1/CES-1/CYP7A1/FXR pathway in high-fat diet-fed rats

Toxicol Appl Pharmacol. 2021 Feb 1:412:115388. doi: 10.1016/j.taap.2020.115388. Epub 2020 Dec 28.

Abstract

Phytosterol diosgenin (DG) exhibits cholesterol-lowering properties. Few studies focused on the underlying mechanism of DG attenuation of hypercholesterolemia by promoting cholesterol metabolism. To investigate the roles of SRB1/CES-1/CYP7A1/FXR pathways in accelerating cholesterol elimination and alleviating hypercholesterolemia, a rat model of hypercholesterolemia was induced by providing a high-fat diet (HFD). Experimental rat models were randomly divided into a normal control (Con) group, HFD group, low-dose DG (LDG) group (150 mg/kg/d), high-dose DG (HDG) group (300 mg/kg) and Simvastatin (Sim) group (4 mg/kg/d). Body weights, serum and hepatic lipid parameters of rats were tested. The expression levels of scavenger receptor class B type I (SRB1), carboxylesterase-1 (CES-1), cholesterol7α- hydroxylase (CYP7A1), and farnesoid X receptor (FXR) were determined. The results showed that DG reduced weight and lowered lipid levels in HFD-fed rats. Pathological morphology analyses revealed that DG notably improved hepatic steatosis and intestinal structure. Further studies showed the increased hepatic SRB1, CES-1, CYP7A1 and inhibited FXR-mediated signaling in DG-fed rats, which contributing to the decrease of hepatic cholesterol. DG also increased intestinal SRB1 and CES-1, inhibiting cholesterol absorption and promoting RCT. The expression levels of these receptors in the HDG group were higher than LDG and Sim groups. These data suggested that DG accelerated reverse cholesterol transport (RCT) and enhanced cholesterol elimination via SRB1/CES-1/CYP7A1/FXR pathway, and DG might be a new candidate for the alleviation of hypercholesterolemia.

Keywords: CYP7A1; Cholesterol metabolism; Diosgenin; FXR; Hypercholesterolemia; SRB1.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Biomarkers / blood
  • Carboxylic Ester Hydrolases / metabolism*
  • Cholesterol / blood*
  • Cholesterol 7-alpha-Hydroxylase / metabolism*
  • Diet, High-Fat
  • Diosgenin / pharmacology*
  • Disease Models, Animal
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / enzymology
  • Hypercholesterolemia / pathology
  • Hypercholesterolemia / prevention & control*
  • Liver / drug effects*
  • Liver / enzymology
  • Liver / pathology
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Scavenger Receptors, Class B / metabolism*
  • Signal Transduction
  • Simvastatin / pharmacology

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Receptors, Cytoplasmic and Nuclear
  • Scarb1 protein, rat
  • Scavenger Receptors, Class B
  • farnesoid X-activated receptor
  • Cholesterol
  • Simvastatin
  • CYP7A1 protein, rat
  • Cholesterol 7-alpha-Hydroxylase
  • Carboxylic Ester Hydrolases
  • Ces1e protein, rat
  • Diosgenin